Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Sell
25
UBX Quote, Financials, Valuation and Earnings
Last price:
$1.12
Seasonality move
:
-7.28%
Day range:
$1.01 - $1.20
52-week range:
$0.94 - $2.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.16x
Volume:
98.1K
Avg. volume:
90.5K
1-year change:
-49.41%
Market cap:
$16.5M
Revenue:
--
EPS (TTM):
-$1.27
Analysts' Opinion
-
Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Unity Biotechnology has an estimated upside of 616.92% from its current price of $0.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $0.98.
Fair Value
-
According to the consensus of 1 analyst, Unity Biotechnology has 616.92% upside to fair value with a price target of $7.00 per share.
UBX vs. S&P 500
-
Over the past 5 trading days, Unity Biotechnology has overperformed the S&P 500 by 0.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Unity Biotechnology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Unity Biotechnology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Unity Biotechnology reported revenues of --.
Earnings Growth
-
Unity Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Unity Biotechnology reported earnings per share of -$0.38.
Enterprise value:
-12.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$53.6M | -$45.3M | -$28.9M | -$9M | -$6.6M | |
| EBITDA | -$50.6M | -$29.4M | -$21M | -$13.9M | -$6.3M | |
| Diluted EPS | -$7.86 | -$3.45 | -$1.27 | -$1.01 | -$0.38 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $135.7M | $84.7M | $102.7M | $49.5M | $30.3M | |
| Total Assets | $175M | $125.7M | $136.4M | $69.3M | $47.1M | |
| Current Liabilities | $16.9M | $13M | $16.8M | $8.6M | $8.8M | |
| Total Liabilities | $76.9M | $68M | $57.8M | $33.1M | $33M | |
| Total Equity | $98.1M | $57.7M | $78.6M | $36.2M | $14.1M | |
| Total Debt | $24.3M | $25.1M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$45.7M | -$41.3M | -$22.5M | -$7.1M | -$5.2M | |
| Cash From Investing | -$15.3M | $45.2M | $19.1M | $14.2M | $6.5M | |
| Cash From Financing | $61.6M | -$19.2M | $4.5M | -$18.4M | -- | |
| Free Cash Flow | -$45.8M | -$41.3M | -$22.5M | -$7.1M | -$5.2M | |
UBX
Sector
Market Cap
$16.5M
$47.7M
Price % of 52-Week High
48.34%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-49.41%
-33.33%
Beta (5-Year)
0.804
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.99
200-day SMA
Sell
Level
$1.42
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$1.07
Relative Strength Index (RSI14)
Buy
Level
54.87
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-84.7274
50-day SMA
Sell
Level
$1.19
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Stock Forecast FAQ
In the current month, UBX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UBX average analyst price target in the past 3 months is $7.00.
-
Where Will Unity Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Unity Biotechnology share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Unity Biotechnology?
Analysts are divided on their view about Unity Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Unity Biotechnology is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Unity Biotechnology's Price Target?
The price target for Unity Biotechnology over the next 1-year time period is forecast to be $7.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UBX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Unity Biotechnology is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of UBX?
You can purchase shares of Unity Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Unity Biotechnology shares.
-
What Is The Unity Biotechnology Share Price Today?
Unity Biotechnology was last trading at $1.12 per share. This represents the most recent stock quote for Unity Biotechnology. Yesterday, Unity Biotechnology closed at $0.98 per share.
-
How To Buy Unity Biotechnology Stock Online?
In order to purchase Unity Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Why Is Adobe Stock Dropping?
Why is Adobe stock dropping? A combination of underwhelming fiscal…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
25
DRUG alert for Jan 3
Bright Minds Biosciences [DRUG] is up 13.55% over the past day.
Buy
56
QMCO alert for Jan 2
Quantum [QMCO] is up 0.83% over the past day.
Buy
78
BMA alert for Jan 3
Banco Macro SA [BMA] is up 12.94% over the past day.
